Senate Hearing Questions Strength Of FDA Post-Market Surveillance
This article was originally published in The Gray Sheet
Executive Summary
An April 13 Senate hearing billed as a look at the medical device approval process turned into a wide-ranging critique of FDA's post-market surveillance of device safety.
You may also be interested in...
GAO Calls For Reforms In FDA Oversight Of Device Recalls
The Government Accountability Office is urging FDA to clarify and strengthen its oversight of medical device recalls.
GAO Calls For Reforms In FDA Oversight Of Device Recalls
The Government Accountability Office is urging FDA to clarify and strengthen its oversight of medical device recalls.
Class I Recalls Surge To Highest Point Ever; FDA Not Sure Why
The number of high-risk Class I medical device recalls skyrocketed to its highest point ever last year, leaving FDA officials to ponder what could have caused the dramatic upswing.